One of the product lines that has helped the bottom line is recall management. Recalls will be a fact of life and many pharma companies would rather hire an outside contractor to perform this function.
The company has a very aggressive growth through acquisition program and completed 6 new acquisitions in the past year.
The stock came to my attention by hitting 10 new highs in the last 20 trading sessions and 4 in the last 5. New highs in this soft market are hard to come by. In the last month the stock has enjoyed a 12.84% price appreciation and trades around 63.79 with a 50 day moving average of 57.61. The stock has a 100% Barchart technical buy rating.
Investors have noticed this stock and over on Motley Fool the CAPS members vote that the stock will outperform the market by a vote of 245 to 15 with the more experienced All Stars agreeing 67 to 8. Of the Wall Street columnists Fool follows it is noted that all 3 articles have been positive.
Wall Street brokerage analysts are high on the stock with 7 buy and 2 hold recommendations published. They feel the sales will increase 16.20% this year and 8.10% next year. Double digit earnings per share increases of 16.70% this year, 13.58% next year and a 5 year compounded EPS growth rate of 16.44% deserves your attention.
This stock has great prospects:
- 2nd largest medical waste management company
- Aggressive growth by acquisition strategy
- Hitting new highs in better than 50% of the recent trading sessions
- Very high investor sentiment
- Wall Street buy recommendations based on increases in sales and double digit EPS growth.
Jim Van Meerten is an investor who writes on financial matters on Financial Tides. Please leave a comment below or email JimVanMeerten@gmail.com
Disclosure: No positions in SRCL at the time of publication
No comments:
Post a Comment